Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Strategic Asset Allocation Index
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Strategic Asset Allocation Index of 35.9% as of September 2023. Strategic assets (PP&E of CN¥2.56 Billion plus long-term investments of CN¥-) total CN¥2.56 Billion, measured against net assets of CN¥7.15 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Guizhou Xinbang Pharmaceutical Co Ltd Strategic Asset Allocation Index (2007–2022)
This chart shows how Guizhou Xinbang Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of September 2023, the index stands at 35.9%, representing strategic assets of CN¥2.56 Billion against net assets of CN¥7.15 Billion CNY. Explore Guizhou Xinbang Pharmaceutical Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Guizhou Xinbang Pharmaceutical Co Ltd (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Guizhou Xinbang Pharmaceutical Co Ltd from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 002390 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 37.8% | CN¥2.67 Billion | CN¥2.67 Billion | CN¥- | CN¥7.07 Billion | ▼ -1.8 pp |
| 2021 | 39.6% | CN¥2.71 Billion | CN¥2.71 Billion | CN¥- | CN¥6.83 Billion | ▼ -5.3 pp |
| 2020 | 44.9% | CN¥2.32 Billion | CN¥2.32 Billion | CN¥- | CN¥5.17 Billion | ▼ -9.5 pp |
| 2019 | 54.5% | CN¥2.75 Billion | CN¥2.75 Billion | CN¥- | CN¥5.05 Billion | ▼ -0.9 pp |
| 2018 | 55.4% | CN¥2.86 Billion | CN¥2.77 Billion | CN¥88.45 Million | CN¥5.17 Billion | ▲ +14.0 pp |
| 2017 | 41.4% | CN¥2.80 Billion | CN¥2.71 Billion | CN¥92.93 Million | CN¥6.76 Billion | ▲ +4.6 pp |
| 2016 | 36.9% | CN¥2.39 Billion | CN¥2.36 Billion | CN¥30.05 Million | CN¥6.49 Billion | ▼ -31.4 pp |
| 2015 | 68.2% | CN¥1.82 Billion | CN¥1.75 Billion | CN¥66.05 Million | CN¥2.67 Billion | ▲ +33.0 pp |
| 2014 | 35.3% | CN¥866.48 Million | CN¥866.48 Million | CN¥- | CN¥2.46 Billion | ▲ +0.3 pp |
| 2013 | 35.0% | CN¥362.08 Million | CN¥362.08 Million | CN¥- | CN¥1.04 Billion | ▲ +2.3 pp |
| 2012 | 32.7% | CN¥334.23 Million | CN¥334.23 Million | CN¥- | CN¥1.02 Billion | ▲ +4.0 pp |
| 2011 | 28.7% | CN¥281.42 Million | CN¥281.42 Million | CN¥- | CN¥979.53 Million | ▲ +7.9 pp |
| 2010 | 20.8% | CN¥199.98 Million | CN¥199.98 Million | CN¥- | CN¥959.70 Million | ▼ -34.9 pp |
| 2009 | 55.8% | CN¥141.04 Million | CN¥141.04 Million | CN¥- | CN¥252.83 Million | ▼ -12.0 pp |
| 2008 | 67.8% | CN¥140.75 Million | CN¥140.75 Million | CN¥- | CN¥207.69 Million | ▼ -12.5 pp |
| 2007 | 80.3% | CN¥139.76 Million | CN¥139.76 Million | CN¥- | CN¥174.08 Million | — |